MAPK3 and myeloproliferative neoplasm: Since genetic targeting of ERK1/2 was able to interfere with MPN phenotype and clone size, we hypothesized that ERK1/2 deficiency in MPN cells could enhance therapeutic effects of JAK2 inhibition by ruxolitinib.